Hefei Revokes Operating Licenses for 665 Second-Class Medical Device Firms

Deep News
06/16

In a move to better regulate the medical device distribution market and strictly uphold safety standards, the city of Hefei has revoked the operating licenses for 665 second-class medical device enterprises this year.

Regulatory authorities discovered during inspections that some companies, after obtaining their second-class medical device operating permits, engaged in violations such as submitting false documentation for their licenses or not operating from their registered business addresses. These actions introduced significant risks into the medical device supply chain. To ensure public safety, the regulatory body has initiated a targeted cleanup campaign with a strict enforcement approach.

For on-site verification, the bureau has distributed the companies' licensing information to local market supervision departments to check the authenticity of the submitted materials and the compliance of their business operations. Furthermore, routine inspections have been intensified, with an annual plan established at the beginning of the year specifying the number of companies to be inspected and the frequency. The focus is on verifying whether companies are still operating from their registered addresses and can consistently ensure product safety and efficacy.

Since the beginning of 2023, Hefei has cumulatively canceled the operating licenses for 8,537 second-class medical device companies, leading to further standardization of market order. Moving forward, the bureau will continue to conduct regular, dynamic reviews of medical device operating qualifications. It aims to improve the market exit mechanism that rewards the competent and eliminates the unfit, reinforce corporate accountability, standardize industry practices, and effectively strengthen the safeguards for public medical device safety.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10